The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 9 , ISSUE 1 ( January, 2008 ) > List of Articles

RESEARCH ARTICLE

Oral Adverse Effects Due to the Use of Nevirapine

Mariela Dutra Gontijo Moura, Maria Inés Barreiros Senna, Davidson Fróis Madureira, Linaena Méricy Silva Fonseca, Ricardo Alves Mesquita

Citation Information : Moura MD, Senna MI, Madureira DF, Fonseca LM, Mesquita RA. Oral Adverse Effects Due to the Use of Nevirapine. J Contemp Dent Pract 2008; 9 (1):84-90.

DOI: 10.5005/jcdp-9-1-84

License: CC BY-NC 3.0

Published Online: 01-01-2008

Copyright Statement:  Copyright © 2008; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP).

Background

NVP is a non-nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus (HIV) infection.

Case Report

A 29-year-old black man, HIV-infected since 1996, began highly active antiretroviral therapy (HAART) with zidovudine, lamivudine, and indinavir. From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss). When the patient presented to our service he was taking NVP, zidovudine, and lamivudine. A whitish plaque in the lips and bilateral buccal mucosa, burning, taste disturbance, and xerostomia were observed. The discontinuation of HAART led to the complete resolution of signs and symptoms. The patient has received follow-up treatment for three years and five months without local or systemic effects observed.

Summary

Unfortunately, the clinical features of the oral adverse effect from NVP are not well known. This paper contributed to the identification of possible reactions in the oral cavity due to antiretroviral medication.

Although HAART is very important in the treatment of HIV, its side effects are responsible for patients’ nonadherence to medications. While more studies are needed to better understand the mechanism of action after suspending HAART, the complete resolution of the signs and symptoms was observed. Therefore, physicians and dentists alike must understand how to identify and prevent these adverse effects in order to further improve HIV patient treatments.

Citation

Moura MGD, Senna MIB, Madureira DF, Fonseca LMS, Mesquita RA. Oral Adverse Effects Due to the Use of Nevirapine. J Contemp Dent Pract 2008 January; (9)1:084-090.


PDF Share
  1. Adverse effects of antiretroviral therapy. Lancet 2000; 356 (9239):1423-30.
  2. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis. 2003; 36(9):1186-90.
  3. Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. J Obstet Gynaecol Res. 2002; 28(6):313-9.
  4. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 89(3):299-304.
  5. HIV and drug allergy. Curr Opin Allergy Clin Immunol. 2001; 1(4):311-6.
  6. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med. 2000; 29(7):336-41.
  7. Orofacial effects of antiretroviral therapies. Oral Dis. 2001; 7(4):205-10.
  8. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 92(6):623-8.
  9. Oral manifestations in the era of HAART. J Natl Med Assoc. 2003; 95(2 Suppl 2):21S-32S.
  10. Human immunodeficiency virus disease: natural history and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(3):266-70.
  11. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002; 34(7):991-1001.
  12. Nevirapine-induced overlap stevensjohnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 1999; 140(5):980-2.
  13. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170(2):229-38.
  14. Sex differences in nevirapine rash. Clin Infect Dis. 2001; 32(1):124-9.
  15. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr. 2003; 33(1):41-6.
  16. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998; 20(6):1071-92.
  17. Failure of a short-term prednisone regimen to prevent nevirapineassociated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001; 28(1):14-8.
  18. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. Clin Infect Dis. 2002; 35(10):1231-7.
  19. White lichenoid lesions of the buccal mucosa in patients with HIV infection. Oral Surg Oral Med Oral Pathol. 1993; 76(4):460-6.
  20. Hypersensitivity reactions in neonates and infants. Dermatol Ther. 2005; 18(2):160-75.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.